Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Charles Mercy Hospital
mi
from
Oregon, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Charles Mercy Hospital
mi
from
Oregon, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Anne Mercy Hospital
mi
from
Toledo, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Anne Mercy Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Guthrie Cancer Center at Guthrie Clinic Sayre
mi
from
Sayre, PA
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Guthrie Cancer Center at Guthrie Clinic Sayre
mi
from
Sayre, PA
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
AnMed Cancer Center
mi
from
Anderson, SC
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
AnMed Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rapid City Regional Hospital
mi
from
Rapid City, SD
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
mi
from
Huntington, WV
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
mi
from
Huntington, WV
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Nicholas Hospital
mi
from
Sheboygan, WI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Nicholas Hospital
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kapiolani Medical Center at Pali Momi
mi
from
'Aiea, HI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kapiolani Medical Center at Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Click here to add this to my saved trials
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope
mi
from
Duarte, CA
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cetuximab (IC) in Triple Negative Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
The Methodist Hospital Cancer Center
mi
from
Houston, TX
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cetuximab (IC) in Triple Negative Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
The Methodist Hospital Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Saint Francis Medical Center
mi
from
Grand Island, NE
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Saint Francis Medical Center
mi
from
Grand Island, NE
Click here to add this to my saved trials
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center (MSKCC)
mi
from
New York, NY
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center (MSKCC)
mi
from
New York, NY
Click here to add this to my saved trials
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Roskilde Hospital
mi
from
Roskilde,
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Roskilde Hospital
mi
from
Roskilde,
Click here to add this to my saved trials
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard
mi
from
Fort Wayne, IN
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials